리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 05월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 MRSA 치료제 시장은 2030년까지 16억 달러에 달할 전망
2023년에 12억 달러로 추정된 세계의 MRSA 치료제 시장은 2030년에는 16억 달러에 달하며, 분석 기간인 2023-2030년 CAGR은 4.4%로 성장할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 당펩티드 & 리포당펩티드 약제 클래스는 CAGR 4.5%를 기록하며, 분석 기간 종료시에는 6억 6,020만 달러에 달할 것으로 예측됩니다. 리포펩티드 약제 클래스별 부문의 향후 7년간의 성장률은 CAGR 4.9%로 추정됩니다.
미국 시장은 3억 5,790만 달러로 추정, 중국은 CAGR 4.2%로 성장 예측
미국의 MRSA 치료제 시장은 2023년에 3억 5,790만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년의 분석 기간에 CAGR 4.2%로 추이하며, 2030년에는 2억 8,350만 달러의 시장 규모에 달할 것으로 예측되고 있습니다. 기타 주목할 만한 지역적 시장으로는 일본과 캐나다가 있으며, 각각 2023-2030년 4.1%와 3.7%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 4.4%로 성장할 것으로 예측되고 있습니다.
2024년의 매력적인 신규 리포트 기능 소개
인플루언서 관여 통계에 대한 풀 액세스
디지털 아카이브와 "MarketGlass" 조사 플랫폼에 대한 무료 액세스. Global Industry Analysts, Inc.의 독자적인 MarketGlass 플랫폼은 전 세계 전문가의 창조성과 시장 지식을 통합적 및 협조적으로 활용할 수 있도록 지원합니다. Global Industry Analysts, Inc.의 최첨단 툴은 시장 참여 기업의 프라이버시와 ID를 보호하면서 세계 클래스의 시장 전망을 가져옵니다. 리포트내 수치, 통계, 시장에 관한 설명은 이 분야의 전문가 및 인플루언서에 의해 공유된 완전하게 큐레이트된 인사이트에 기반하고 있습니다.
실시간 데이터 시뮬레이터·툴 및 맞춤형 리포트 작성 기능을 갖춘 인터랙티브 앙케이트에 참가하실 수 있습니다.
기업간 스마트한 의견교환을 위한 피어 협업·인터랙티브 플랫폼에 대한 풀 클라이언트 액세스
1년간 무료 리포트 업데이트
주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지
복수 지역에 걸친 기업 시장 입지 분석(호조/활발/니치/마이너)
전문가/인플루언서 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연의 YouTube 비디오에 대한 액세스
2024년 세계 경제에 기대하는 것
금융긴축과 이에 따른 금리 상승에 의해 발생하는 지정학적, 경제적 불안정성이 2024년 격동의 상황을 야기할 것으로 생각됩니다. 중동에서의 적대 행위 및 더욱 더 빈발하는 기후 재해 등 몇개의 요인이 회복의 길에 계속 압력을 가할 것으로 생각됩니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도 및 미국을 비롯한 G21 국가의 선거는 자본 흐름 및 투자전략에 영향을 미칠 가능성이 있습니다. 인도가 세계 투자처로서 주목받는 한편, 미국을 기반으로 하는 하이테크 기업은 재능과 자본의 역동적인 에코시스템에 의해 지원되며 계속 우위를 유지할 것으로 생각됩니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 감속하고 있으나 안정적이며, 규제 환경도 정비되고 있는 것으로 인해 고성장 가능성을 요구하는 투자자에게 계속 매력적입니다. 유럽은 금융긴축정책과 경기후퇴 리스크와의 싸움이 계속되며, 영국은 전망이 가장 어렵고, 2024년 경기후퇴 리스크가 가장 높습니다 중국은 정부지출과 개인소비의 개선에 의지한 성장이 기대되며 계속해서 와일드 카드로 남아 있습니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 과제를 둘 다 제공할 것으로 생각됩니다. 성장에 대한 촉매로서 변동성을 수용하는 것과 함께 투자 판단 결정에서 민첩성과 전략적 선견성이 생존을 위해 여전히 중요할 것입니다.
조사 대상 기업의 예(총 23건)
Absynth Biologics
Allergan PLC
AmpliPhi Biosciences Corporation
AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Baxter International, Inc.
Cempra, Inc.
CrystalGenomics Inc.
Debiopharm Group
Galapagos NV
GlaxoSmithKline plc
Innovation Pharmaceuticals Inc.
Kyorin Pharmaceutical Co., Ltd.
Lytix Biopharma AS
Melinta Therapeutics, Inc.
Merck & Co., Inc.
Nabriva Therapeutics US, Inc.
NovaDigm Therapeutics, Inc.
Paratek Pharmaceuticals, Inc.
Pfizer, Inc.
R-Pharm-US LLC
Savara Inc.
Sealife PHARMA GMBH
Sequella, Inc.
The Medicines Company
Theravance Biopharma, Inc.
XBiotech Inc.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
세계의 기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global MRSA Drugs Market to Reach $1.6 Billion by 2030
The global market for MRSA Drugs estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Glycopeptides & Lipoglycopeptides Drug Class, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$660.2 Million by the end of the analysis period. Growth in the Lipopeptides Drug Class segment is estimated at 4.9% CAGR for the next 7-year period.
The U.S. Market is Estimated at $357.9 Million, While China is Forecast to Grow at 4.2% CAGR
The MRSA Drugs market in the U.S. is estimated at US$357.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$283.5 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 23 Featured) -
Absynth Biologics
Allergan PLC
AmpliPhi Biosciences Corporation
AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Baxter International, Inc.
Cempra, Inc.
CrystalGenomics Inc.
Debiopharm Group
Galapagos NV
GlaxoSmithKline plc
Innovation Pharmaceuticals Inc.
Kyorin Pharmaceutical Co., Ltd.
Lytix Biopharma AS
Melinta Therapeutics, Inc.
Merck & Co., Inc.
Nabriva Therapeutics US, Inc.
NovaDigm Therapeutics, Inc.
Paratek Pharmaceuticals, Inc.
Pfizer, Inc.
R-Pharm-US LLC
Savara Inc.
Sealife PHARMA GMBH
Sequella, Inc.
The Medicines Company
Theravance Biopharma, Inc.
XBiotech Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
MRSA Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World MRSA Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 14: World Recent Past, Current & Future Analysis for Glycopeptides & Lipoglycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Glycopeptides & Lipoglycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Glycopeptides & Lipoglycopeptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Lipopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Lipopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Lipopeptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Oxazolidinones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Oxazolidinones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Oxazolidinones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
JAPAN
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
CHINA
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 65: China Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
EUROPE
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
FRANCE
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 86: France Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
GERMANY
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
UNITED KINGDOM
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Europe 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Europe 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Asia-Pacific 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Asia-Pacific 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 140: Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of World 16-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 143: Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of World Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of World 16-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2024 & 2030
TABLE 146: Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of World 16-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
